Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Parenteral Anticoagulants
2012 Standout
Prevalence of Left Atrial Thrombus and Dense Spontaneous Echo Contrast in Patients With Short-Term Atrial Fibrillation < 48 Hours Undergoing Cardioversion: Value of Transesophageal Echocardiography to Guide Cardioversion
2009
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
2009 Standout
Oral Anticoagulant Therapy
2012 Standout
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials
2003
Therapeutic applications of compounds in the Magnolia family
2011 Standout
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
2012
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
2003
Resting Heart Rate in Cardiovascular Disease
2007 Standout
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
2018 Standout
Atrial Fibrillation and Congestive Heart Failure: Risk Factors, Mechanisms, and Treatment
2006
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
2007
In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes
2009 StandoutNobel
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
2004
Antithrombotic Therapy in Atrial Fibrillation
2004
The role of vagal function in the risk for cardiovascular disease and mortality
2006 Standout
Relation of Vigorous Exercise to Risk of Atrial Fibrillation
2009
Dronedarone for prevention of atrial fibrillation: A dose-ranging study
2003
Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
2006
Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues
2003
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
2005
Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation
2006
Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias
2006
Gender differences in arrhythmias
2002
Transcatheter closure of patent foramen ovale in older adults
2006
The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors
2009 Standout
Rate vs Rhythm Control in Patients With Atrial Fibrillation
2005
Antithrombotic Therapy in Atrial Fibrillation
2008
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
2006
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture
2011 StandoutNobel
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
2019
Worldwide Epidemiology of Atrial Fibrillation
2013 Standout
Perception of Atrial Fibrillation Before and After Radiofrequency Catheter Ablation
2005
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation
2003
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
2015
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2006
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Mortality in Patients After a Recent Myocardial Infarction
2004
Works of Stephen Marcello being referenced
Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response
2000
Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response
2002
Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials
2003
The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction
2004
Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation
2001
Azimilide Dihydrochloride, a Novel Antiarrhythmic Agent
1998
Asymptomatic or “Silent” Atrial Fibrillation
2003